Group 1 - The article emphasizes the importance of sustained profitability over mere valuation in driving investment returns, highlighting strong margins, stable and expanding free cash flow, and high returns on invested capital as key indicators [1] - The author identifies Airbnb (NASDAQ: ABNB) as a prime example of a company that may not align with consumer preferences but presents a valuable investment opportunity [1] - The investment strategy focuses on undervalued growth stocks and high-quality dividend growers within the U.S. and European equities markets [1] Group 2 - The author manages a portfolio publicly on eToro, qualifying as a Popular Investor, which allows others to replicate real-time investment decisions [1] - The interdisciplinary background of the author, including Economics, Classical Philology, Philosophy, and Theology, enhances both quantitative analysis and market narrative interpretation [1] - The investment philosophy aims to balance asset accumulation with the freedom to choose work that aligns with personal expression, rather than seeking to escape work altogether [1]

Group 1 - The article discusses the recent earnings report of McDonald's Corporation (NYSE: MCD) following the earnings reports of major banks and tech companies, indicating a significant focus on the fast-food giant's performance [1] - McDonald's is positioned as a key player in the consumer sector, with its earnings report expected to provide insights into consumer spending trends and overall economic health [1] Group 2 - The author emphasizes the importance of sustained profitability, highlighting strong margins, stable and expanding free cash flow, and high returns on invested capital as critical factors for long-term investment success [2] - The investment strategy focuses on undervalued growth stocks and high-quality dividend growers, suggesting a preference for companies that demonstrate consistent financial performance [2]

Core Viewpoint - Intuitive Machines stock has shown resilience despite a downgrade from Bank of America, indicating potential investor optimism and future growth prospects [2][4][5]. Group 1: Stock Performance and Analyst Ratings - Bank of America analyst Ronald Epstein lowered the price target for Intuitive Machines stock from $16 to $10.50, resulting in an "underperform" rating [2]. - Despite the downgrade, Intuitive Machines stock increased by 1.2% initially and continued to rise, gaining 5.1% by mid-morning [2][4]. - The stock's performance this year has been bolstered by a report of positive free cash flow of $13.3 million in Q1 [5]. Group 2: Future Profitability and Cash Flow Concerns - Analysts predict that Intuitive Machines will not achieve sustained profitability until at least 2027 and consistent positive free cash flow until 2028 [6]. - Management has cautioned about potential "cash receipt lumpiness" in Q2, which may lead to negative free cash flow [5][6]. Group 3: Growth Opportunities - Intuitive Machines has secured multiple NASA contracts for lunar missions, a Near Space Network communications contract, and is developing Earth reentry vehicles for semiconductor and space pharmaceutical clients, indicating a promising future [7].

Group Overview - IBA reported a solid start to 2025, driven by strong market momentum in Proton Therapy and positive trends in Dosimetry [4][6] - The company has a backlog of €1.5 billion in IBA Clinical Equipment and Services, with a positive net cash position of €9 million [6] - A share buyback program is ongoing, with 582,849 shares purchased as of May 19, 2025, against a target of 650,000 by year-end [6] Proton Therapy and Dosimetry - There are currently 38 ongoing proton therapy projects, including 8 ProteusPLUS and 30 ProteusONE systems, with 9 installations underway [7] - Strong commercial activity is noted in the Asia-Pacific region, with significant contracts signed in India and Taiwan [7] - The integration of Radcal Corporation is back on track, supporting profitability in Dosimetry [7] Product Innovations - IBA launched the QUASAR GRID system and myQA Blue Phantom, enhancing quality assurance solutions [7] - Two additional sales in Radio Pharma Solutions were activated post-period, including a contract in Taiwan [7] - The company introduced CASSY, a new compact synthesizer aimed at improving efficiency in radiotracers production [7] Financial Outlook - IBA maintains its one-year guidance for 2025, expecting a REBIT of at least €25 million, supported by positive performance in Proton Therapy [9] - The mid-term outlook (2024-2028) indicates confidence in sustained profitability while monitoring macroeconomic conditions [10] - Revenue is projected to grow at a normalized frontloaded rate of 5-7% CAGR, with OPEX expected to be up to 30% of sales per annum [14]